News & Updates

Show Multimedia Only

Freshwater fish-based diet eases liver steatosis in NAFLD patients

02 Nov 2022 by

Adherence to a freshwater fish-based diet helps regulate the gut microbiota and its metabolites, suggesting benefits in individuals with nonalcoholic fatty liver disease (NAFLD), reveals a study.

02 Nov 2022

TNF inhibition beyond 24 weeks: How safe in pregnant mums?

02 Nov 2022 by

Continued treatment with tumor necrosis factor (TNF) inhibitors after 24 weeks of pregnancy appears safe and is associated with lower chances of maternal inflammatory bowel disease (IBD) relapse, without increasing adverse neonatal outcomes, new research suggests.

02 Nov 2022

Original New Drug Application Approvals by US FDA (16 - 31 October 2022)

02 Nov 2022

New drug applications approved by US FDA as of 16 - 31 October 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

02 Nov 2022

MRI-derived biomarkers pinpoint NASH patients at high risk of progression

31 Oct 2022

The quantitative magnetic resonance imaging (MRI)-derived biomarkers cT1 and liver fat demonstrate good performance for identifying patients with nonalcoholic steatohepatitis (NASH) who have the highest risk of disease progression, as reported in a study.

31 Oct 2022

4-percent AET best predictor of PPI discontinuation

28 Oct 2022

An acid exposure time (AET) of 4.0 percent is a reliable prognostic marker of proton pump inhibitor (PPI) therapy discontinuation, a study has shown. In addition, 96 hours of monitoring works better than 48 hours in predicting PPI cessation.

28 Oct 2022

Does obesity raise risk of hospitalization IBD patients?

27 Oct 2022

Obesity does not increase the likelihood of hospitalization among biologic-treated patients with inflammatory bowel disease (IBD), suggests a recent study.

27 Oct 2022

Exercise improves quality of life of patients with advanced liver disease

27 Oct 2022

Exercise interventions may result in positive outcomes on muscular or cardiorespiratory fitness and quality of life in patients with advanced liver disease, suggest the results of a systematic review.

27 Oct 2022

Metformin not protective against older-onset IBD

26 Oct 2022

The use of metformin does not appear to confer any benefits in terms of reducing the risk of older-onset inflammatory bowel disease (IBD), a study has found.

26 Oct 2022

Treatment failure risk in older IBD patients higher with vedolizumab vs TNF antagonists

25 Oct 2022

The use of vedolizumab in the treatment of older patients with inflammatory bowel disease (IBD) appears to not only pose a higher risk of treatment failure but also offer no significant safety advantage when compared with tumour necrosis factor (TNF) antagonists, according to a study.

25 Oct 2022

Early surgery cuts reoperation risk, immunomodulator exposure in Crohn’s disease

22 Oct 2022

Patients with Crohn’s disease (CD) who undergo resection within 29 days of diagnosis are less likely to need reoperation in the future and have lower levels of immunomodulator exposure, a recent study has found.

22 Oct 2022

News & Updates

Showing Gastroenterology articles

Showing

Specialty:

Freshwater fish-based diet eases liver steatosis in NAFLD patients

TNF inhibition beyond 24 weeks: How safe in pregnant mums?

Original New Drug Application Approvals by US FDA (16 - 31 October 2022)

MRI-derived biomarkers pinpoint NASH patients at high risk of progression

4-percent AET best predictor of PPI discontinuation

Does obesity raise risk of hospitalization IBD patients?

Exercise improves quality of life of patients with advanced liver disease

Metformin not protective against older-onset IBD

Treatment failure risk in older IBD patients higher with vedolizumab vs TNF antagonists

Early surgery cuts reoperation risk, immunomodulator exposure in Crohn’s disease